相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway
Li Zhang et al.
MEDICAL ONCOLOGY (2020)
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Yangjiong Xiao et al.
CELLULAR ONCOLOGY (2020)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Silencing TTK expression inhibits the proliferation and progression of prostate cancer
Saipeng Chen et al.
EXPERIMENTAL CELL RESEARCH (2019)
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells
Simona Ceccarelli et al.
STEM CELLS INTERNATIONAL (2019)
Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
Hui Zheng et al.
CANCER MEDICINE (2019)
PI3K Inhibitors in Breast Cancer Therapy
Haley Ellis et al.
CURRENT ONCOLOGY REPORTS (2019)
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
Dominik Bieg et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2018)
TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer
Jamie L. King et al.
ONCOGENESIS (2018)
TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
Guido J. R. Zaman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
Emma C. Fields et al.
FRONTIERS IN ONCOLOGY (2017)
Leptin-Induced JAK/STAT Signaling and Cancer Growth
Mckay Mullen et al.
VACCINES (2016)
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
A. R. R. Maia et al.
ANNALS OF ONCOLOGY (2015)
Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway
Nan Shao et al.
CANCER LETTERS (2015)
Targeting PI3K/AKT/mTOR network for treatment of leukemia
Jessika Bertacchini et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
A molecular view of cisplatin's mode of action: interplay with DNA bases and acquired resistance
M. Paula M. Marques et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2015)
p53 protein aggregation promotes platinum resistance in ovarian cancer
Y. Yang-Hartwich et al.
ONCOGENE (2015)
Effect of Withaferin A on A549 Cellular Proliferation and Apoptosis in Non-small Cell Lung Cancer
Yong Cai et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs
Bakhos A. Tannous et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The Spindle Assembly Checkpoint
Pablo Lara-Gonzalez et al.
CURRENT BIOLOGY (2012)
DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Euan A. Stronach et al.
NEOPLASIA (2011)
Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy
K Nakayama et al.
CLINICAL CANCER RESEARCH (2004)
Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells
E Papouli et al.
CANCER RESEARCH (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
A family of drug transporters: The multidrug resistance-associated proteins
P Borst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
